Reflusod: protective barrier against reflux and heartburn
Heartburn, gastroesophageal reflux, acid regurgitation and gastric acidity are very widespread problems in both adults and children. These disorders can appear after meals, during the night or in the presence of slow digestion and are often associated with irritation of the esophageal mucosa, a feeling of gastric heaviness and digestive discomfort.
In mild or recurrent forms of gastroesophageal reflux, it may be useful to use medical devices that help protect the mucosa and reduce the contact of gastric acids with the esophagus. Reflusod is an oral solution formulated with sodium alginate, hyaluronic acid and simethicone, developed for the symptomatic treatment of problems associated with gastroesophageal reflux.
Gastroesophageal reflux and acidity: causes and symptoms
Gastroesophageal reflux is a condition characterized by the rise of gastric contents towards the esophagus, with consequent irritation of the gastroesophageal mucosa. It can manifest occasionally or become recurrent, especially in the presence of slow digestion, excessive gastric acidity or alteration of the gastroesophageal barrier.
Among the factors that can favor reflux we find:
- large or high-fat meals
- stress and poor digestion
- excessive production of gastric acids
- bloating and abdominal tension
- increased gastric pressure
- alterations in gastroesophageal function
The most frequent symptoms include heartburn, acid regurgitation, gastric acidity, retrosternal discomfort and a feeling of heaviness after meals. In some cases, reflux cough, gastric bloating and persistent digestive discomfort may also appear. In infants and children, reflux can instead manifest with frequent regurgitation, irritability and difficulties after feeding.
What is Reflusod and what is it for
Reflusod is a medical device in oral solution formulated for the support of symptoms associated with gastroesophageal reflux, acidity and irritation of the esophageal mucosa. The formulation combines sodium alginate, low molecular weight hyaluronic acid, simethicone and myrrh extract to offer a protective and soothing action on the gastroesophageal tract.
Thanks to its viscous formulation, the product adheres to the esophageal mucosa forming a protective film useful to limit direct contact with gastric acids and to improve digestive comfort.
The product contributes to:
- creating a protective barrier against acid reflux
- protecting and hydrating the gastroesophageal mucosa
- reducing acidity and heartburn
- improving digestive comfort
- contributing to the relief of bloating and gastric distension
Sodium alginate and hyaluronic acid: protection of the gastroesophageal mucosa
One of the distinctive elements of Reflusod is the presence of sodium alginate combined with low molecular weight hyaluronic acid.
Sodium alginate creates a viscous barrier that helps to limit the rise of gastric contents towards the esophagus, thus contributing to reducing the irritation caused by gastric acids and to improving gastroesophageal well-being.
Hyaluronic acid contributes instead to keeping the mucosa hydrated and supports the protection of the irritated gastroesophageal epithelium. The formulation is also enriched with myrrh extract, an ingredient used for its emollient and soothing properties on the mucosa exposed to acid reflux.
Simethicone and reflux associated with gastric bloating
Reflusod also contains simethicone, an ingredient used in problems associated with gastric gas and abdominal tension.
Simethicone contributes to reducing the surface tension of gas bubbles present in the gastric contents, facilitating their elimination. This mechanism helps to reduce the pressure exerted by gas on the gastric contents and can contribute to improving bloating, flatulence and digestive discomfort associated with reflux.
The combination of sodium alginate, hyaluronic acid and simethicone therefore allows a comprehensive approach to the support of the gastroesophageal mucosa and digestive comfort in problems associated with reflux and gastric acidity.
Clinical evidence on Reflusod
The clinical documentation of Reflusod reports an observational study sponsored by Gruppo Farmaimpresa and conducted on 40 patients, including adults and infants, with problems associated with gastroesophageal reflux and symptoms related to acidity and irritation of the gastroesophageal mucosa. The study evaluated the efficacy of the product after 3 weeks of treatment in infants and 4 weeks in adults.
The results showed significant improvements in several symptoms associated with gastroesophageal reflux, confirming the potential benefit of the formulation in supporting gastroesophageal and digestive comfort.
In adults, the following were observed:
- reduction in heartburn (-100%)
- reduction in heartburn after meals (-100%)
- improvement in pain during swallowing (-77%)
- reduction in nighttime reflux and symptoms that disturb sleep (-100%)
In infants, the following were reported:
- reduction in regurgitation episodes (-100%)
- improvement in irritability (-100%)
- reduction in hiccups (-95%)
- improvement in respiratory difficulties associated with reflux (-100%)
The study also showed an improvement in GERD-HRQL scores in adults and I-GERQ-R parameters in infants after treatment with Reflusod, suggesting an overall improvement in quality of life and symptoms related to gastroesophageal reflux.
These data support the use of formulations containing sodium alginate, hyaluronic acid and simethicone for the support of symptoms associated with gastroesophageal reflux, gastric acidity and irritation of the esophageal mucosa.
We are certified manufacturers of food supplements, medical devices and cosmetics. Reflusod is available for B2B and private label projects with complete formulative, regulatory and manufacturing support.
